Aurora And MedReleaf Australia Launch IndiMed Tempo 26, Expanding Product Offerings For Medical Cannabis Patients

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB),and MedReleaf Australia launched IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme. Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.

"We are proud to further expand the variety of high-quality medical cannabis products that Australian patients can access through the MedReleaf Concession Scheme, and with the addition of Tempo 26, doctors and patients now have more control and choice about their medical cannabis treatment than ever before," stated Miguel Martin, CEO of Aurora Cannabis. "We are strongly committed to our patient-first approach to cannabis and ensuring access to medical patients, in Australia, and around the world."

The MedReleaf Concession Scheme was developed by MedReleaf Australia and Aurora to provide products and enhance patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme. Through the MedReleaf Concession Scheme, patients can access compassionate pricing, specifically for those with Pensioner Concession Cards, Commonwealth Seniors Health Cards, Health Care Cards, and Veterans Cards.

Aurora currently holds a 10% ownership stake in MedReleaf Australia, a fully licensed, private company.

Photo by Thiago Patriota on Unsplash

Related News

Aurora Repurchases ~$34.3M Of Convertible Notes, Saving $1.9M In Annualized Interest Payments

New Leaf Ventures Enters Into Genetics Supply Agreement With CannaPharmaRX

Aurora Cannabis Files Preliminary Base Shelf Prospectus